Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma

NCT02667886 is registered in ClinicalTrials.gov with X4 Pharmaceuticals as lead sponsor.

NCT NCT02667886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02667886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma
Lead sponsor
X4 Pharmaceuticals
Phase
Phase 1/2
Overall status
Completed
Start date
April 27, 2016
Completion date
April 14, 2022
Enrollment
74 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma